The stock of Medgenics Inc (NASDAQ:MDGN) is a huge mover today! About 187,023 shares traded hands or 1.04% up from the average. Medgenics Inc (NASDAQ:MDGN) has risen 9.76% since April 27, 2016 and is uptrending. It has outperformed by 4.53% the S&P500.
The move comes after 8 months negative chart setup for the $200.33 million company. It was reported on Nov, 30 by Barchart.com. We have $4.75 PT which if reached, will make NASDAQ:MDGN worth $14.02M less.
Analysts await Medgenics Inc (NASDAQ:MDGN) to report earnings on February, 15. They expect $-0.33 earnings per share, down 32.00% or $0.08 from last year’s $-0.25 per share. After $-0.29 actual earnings per share reported by Medgenics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.
According to Zacks Investment Research, “Medgenics, Inc. is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company’s Biopump Platform Technology uses the patient’s own tissue for the treatment of a range of chronic diseases. Its products include EPODURE focused on the treatment of chronic renal anemia and INFRADURE focused on the treatment of hepatitis C. Medgenics, Inc. is based in Vienna, Virginia.”
Insitutional Activity: The institutional sentiment decreased to 1.67 in Q2 2016. Its down 0.77, from 2.44 in 2016Q1. The ratio is negative, as 2 funds sold all Medgenics Inc shares owned while 14 reduced positions. 14 funds bought stakes while 25 increased positions. They now own 15.20 million shares or 11.31% more from 13.66 million shares in 2016Q1.
Bridgeway Cap Mngmt holds 0.01% or 157,500 shares in its portfolio. Voya Inv Management Ltd holds 12,471 shares or 0% of its portfolio. Oxford Asset Management holds 0.01% of its portfolio in Medgenics Inc (NASDAQ:MDGN) for 23,059 shares. Blackrock Invest Limited Company accumulated 0% or 89,373 shares. Schwab Charles Investment Management holds 0% of its portfolio in Medgenics Inc (NASDAQ:MDGN) for 44,012 shares. Qvt Financial Lp has 0.31% invested in the company for 848,800 shares. Opaleye Management holds 260,000 shares or 1.41% of its portfolio. Moreover, Legal General Group Inc Public Lc has 0% invested in Medgenics Inc (NASDAQ:MDGN) for 4,560 shares. Creative Planning holds 0% of its portfolio in Medgenics Inc (NASDAQ:MDGN) for 3,000 shares. Adage Cap Partners Grp Ltd Liability last reported 2.10 million shares in the company. Moreover, Carl Domino has 0.17% invested in Medgenics Inc (NASDAQ:MDGN) for 33,273 shares. Blackrock Institutional Na last reported 0% of its portfolio in the stock. Vanguard Group Incorporated last reported 0% of its portfolio in the stock. White Pine Limited Co holds 20,000 shares or 0.05% of its portfolio. Tiaa Cref Mngmt Lc last reported 0% of its portfolio in the stock.
More important recent Medgenics Inc (NASDAQ:MDGN) news were published by: Fool.com which released: “Why Medgenics Inc.’s Shares Are Down Big Today” on June 21, 2016, also Quotes.Wsj.com published article titled: “Medgenics Inc. MDGN (US: Nasdaq)”, Globenewswire.com published: “Medgenics Acquires Phase 2-Ready CNS Program: NFC-1” on September 09, 2015. More interesting news about Medgenics Inc (NASDAQ:MDGN) was released by: Marketwired.com and their article: “Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD” with publication date: June 06, 2016.
MDGN Company Profile
Medgenics, Inc., incorporated on January 27, 2000, is a clinical-stage biopharmaceutical company. The Firm focuses on genomic medicine. The Firm is engaged in the development of NFC-1. NFC-1 is a non-stimulant metabotropic glutamate receptor (mGluR) neuromodulator for the treatment of mGluR network mutation positive Attention Deficit Hyperactivity Disorder (ADHD), as well as neuropsychiatric symptoms resulting from a related genetic disorder, 22q11.2 Deletion Syndrome (22q11.2 DS). The Firm has completed a Phase Ib clinical of NFC-1 in adolescents with ADHD and disruptions in the mGluR gene network.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.